These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1600592)

  • 1. Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.
    Kreis W; Lesser M; Budman DR; Arlin Z; DeAngelis L; Baskind P; Feldman EJ; Akerman S
    Cancer Chemother Pharmacol; 1992; 30(2):126-30. PubMed ID: 1600592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
    Damon LE; Plunkett W; Linker CA
    Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and leukemic cell pharmacokinetics of high-dose N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute leukemia patients.
    Yoshida T; Kobayashi K; Okabe Y; Okumura H; Matano S; Kanno M; Takeda Y; Ohtake S; Nakamura S; Matuda T
    J Clin Pharmacol; 1994 Jan; 34(1):52-9. PubMed ID: 8132852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
    Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Liliemark JO; Adams TM; Nowak B; Estey E; Kantarjian H; Keating MJ
    Cancer Res; 1987 Jun; 47(11):3005-11. PubMed ID: 3471322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
    Yamauchi T; Kawai Y; Kishi S; Goto N; Urasaki Y; Imamura S; Fukushima T; Yoshida A; Iwasaki H; Tsutani H; Masada M; Ueda T
    Jpn J Cancer Res; 2001 May; 92(5):546-53. PubMed ID: 11376564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
    Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.
    Liliemark JO; Plunkett W; Dixon DO
    Cancer Res; 1985 Nov; 45(11 Pt 2):5952-7. PubMed ID: 4053067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of Ara-C metabolism in vitro to therapeutic response in acute myeloid leukaemia.
    Harris AL; Grahame-Smith DG
    Cancer Chemother Pharmacol; 1982; 9(1):30-5. PubMed ID: 6958391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W; Chan K; Budman DR; Schulman P; Allen S; Weiselberg L; Lichtman S; Henderson V; Freeman J; Deere M
    Cancer Res; 1988 Mar; 48(5):1337-42. PubMed ID: 3342412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-beta-D-arabinofuranosylcytosine (ara-C) deamination in human leukemic myeloblasts is not a mechanism of resistance to ara-C therapy.
    Harris AL
    Cancer Res; 1981 Jul; 41(7):2977-9. PubMed ID: 6941850
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
    Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V; Xu YZ; Estey E
    Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.